# Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Canonical URL: https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting
Ticker: PLRX
Company: Pliant Therapeutics
Source: Pliant Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.pliantrx.com
## Summary

Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society

## Article Body
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society
## Recent Company News
- 2026-06-25 13:46 EST — [Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-announces-upcoming-presentation-at-the-2026-american-society-of-clinical-oncology-annual-meeting) — Source: Pliant Therapeutics
- 2026-06-25 13:46 EST — [Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-first-quarter-2026-financial-results) — Source: Pliant Therapeutics
- 2026-06-25 13:46 EST — [Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-second-quarter-2025-financial-results) — Source: Pliant Therapeutics
- 2026-06-25 13:46 EST — [Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-provides-corporate-update-and-reports-third-quarter-2025-financial-results) — Source: Pliant Therapeutics
- 2026-06-25 13:46 EST — [Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference](https://biopharmsignal.com/news/PLRX/pliant-therapeutics-to-participate-in-the-piper-sandler-healthcare-conference) — Source: Pliant Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)